Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24983586 | 0.83 | P4HTM (0.55) | P4HTMAPPPTGER1MCL1NR4A2 | |
| SCHEMBL30892452 | 0.83 | P4HTM (0.55) | P4HTMAPPPTGER1MCL1NR4A2 | |
| SCHEMBL16727133 | 0.82 | P4HTM (0.54) | P4HTMAPPPTGER1MCL1NR4A2 | |
| SCHEMBL12079449 | 0.79 | L3MBTL1 (0.47) | L3MBTL1 | |
| SCHEMBL29254808 | 0.78 | MCL1 (0.57) | P4HTMMCL1NR4A2NR4A1NR4A3 | |
| SCHEMBL31086447 | 0.78 | MCL1 (0.57) | P4HTMMCL1NR4A2NR4A1NR4A3 | |
| SCHEMBL12076414 | 0.78 | CTSV (0.51) | P4HTMPTGER1MCL1NR4A2NR4A1 | |
| SCHEMBL4652574 | 0.77 | APP (0.67) | P4HTMAPPMCL1MEN1KMT2A | |
| SCHEMBL24455273 | 0.76 | L3MBTL1 (0.45) | L3MBTL1 | |
| SCHEMBL29687741 | 0.76 | L3MBTL1 (0.45) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | BCL2, BCL2L2, BCL2L1 | P4HTM 3719/4885APP 575/4885PTGER1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.